Journal: | Brazilian journal of medical and biological research |
Database: | PERIÓDICA |
System number: | 000349534 |
ISSN: | 0100-879X |
Authors: | Ortiz, R.A.M1 Calafatti, S.A1 Moraes, L.A1 Deguer, M1 Ecclissato, C.C1 Marchioretto, M.A.M1 Ribeiro, M.L1 Bernasconi, G1 Pedrazzoli-Junior, J1 |
Institutions: | 1Universidade Sao Francisco, Unidade Integrada de Farmacologia e Gastroenterologia, Braganca Paulista, Sao Paulo. Brasil |
Year: | 2007 |
Season: | Mar |
Volumen: | 40 |
Number: | 3 |
Pages: | 383-389 |
Country: | Brasil |
Language: | Inglés |
Document type: | Artículo |
Approach: | Experimental, aplicado |
English abstract | The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection. Thirteen H. pylori-infected and 10 non-infected healthy volunteers were enrolled in a study with an open-randomized two-period crossover design and a 21-day washout period between phases. Plasma concentrations of clarithromycin in subjects with and without lansoprazole pre-treatment were measured by liquid chromatography coupled to a tandem mass spectrometer. Clarithromycin Cmax and AUC0-10 h were significantly reduced after lansoprazole administration. In addition, lansoprazole treatment of the H. pylori-positive group resulted in a statistically significant greater reduction in Cmax (40 vs 15%) and AUC0-10 h (30 vs 10%) compared to lansoprazole-treated H. pylori-negative subjects. Thus, treatment with lansoprazole for 5 days reduced bioavailability of clarithromycin, irrespective of H. pylori status. This reduction, however, was even more pronounced in H. pylori-infected individuals |
Disciplines: | Medicina |
Keyword: | Farmacología, Gastroenterología, Ulcera péptica, Claritromicina, Biodisponibilidad, Farmacocinética, Lansoprazol, Helicobacter pylori |
Keyword: | Medicine, Gastroenterology, Pharmacology, Peptic ulcer, Clarithromycin, Bioavailability, Pharmacokinetics, Lansoprazole, Helicobacter pylori |
Full text: | Texto completo (Ver HTML) |